ViewRay Competitors

ViewRay (NASDAQ:VRAY) and InMode (NASDAQ:INMD) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares ViewRay and InMode's top-line revenue, earnings per share and valuation.

InMode has higher revenue and earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than InMode, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ViewRay and InMode's net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.0% of ViewRay shares are held by institutional investors. Comparatively, 22.6% of InMode shares are held by institutional investors. 15.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, InMode has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for ViewRay and InMode, as provided by MarketBeat.com.

ViewRay currently has a consensus target price of $4.4286, indicating a potential upside of 15.93%. InMode has a consensus target price of $47.75, indicating a potential upside of 10.15%. Given ViewRay's higher possible upside, analysts clearly believe ViewRay is more favorable than InMode.

Summary

InMode beats ViewRay on 10 of the 14 factors compared between the two stocks.

ViewRay (NASDAQ:VRAY) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, valuation, analyst recommendations and earnings.

Valuation & Earnings

This table compares ViewRay and BioLife Solutions' top-line revenue, earnings per share and valuation.

BioLife Solutions has lower revenue, but higher earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares ViewRay and BioLife Solutions' net margins, return on equity and return on assets.

Institutional and Insider Ownership

83.0% of ViewRay shares are held by institutional investors. Comparatively, 51.1% of BioLife Solutions shares are held by institutional investors. 15.5% of ViewRay shares are held by company insiders. Comparatively, 22.3% of BioLife Solutions shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Volatility & Risk

ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.53, suggesting that its share price is 53% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations for ViewRay and BioLife Solutions, as provided by MarketBeat.com.

ViewRay currently has a consensus target price of $4.4286, indicating a potential upside of 15.93%. BioLife Solutions has a consensus target price of $30.2222, indicating a potential downside of 8.28%. Given ViewRay's higher possible upside, analysts clearly believe ViewRay is more favorable than BioLife Solutions.

Summary

BioLife Solutions beats ViewRay on 10 of the 14 factors compared between the two stocks.

Natus Medical (NASDAQ:NTUS) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, dividends, risk, profitability, earnings and institutional ownership.

Insider and Institutional Ownership

90.4% of Natus Medical shares are owned by institutional investors. Comparatively, 83.0% of ViewRay shares are owned by institutional investors. 1.5% of Natus Medical shares are owned by company insiders. Comparatively, 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Natus Medical has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Natus Medical and ViewRay, as reported by MarketBeat.com.

ViewRay has a consensus price target of $4.4286, indicating a potential upside of 15.93%. Given ViewRay's stronger consensus rating and higher probable upside, analysts plainly believe ViewRay is more favorable than Natus Medical.

Profitability

This table compares Natus Medical and ViewRay's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Natus Medical and ViewRay's top-line revenue, earnings per share and valuation.

Natus Medical has higher revenue and earnings than ViewRay. ViewRay is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

Summary

Natus Medical beats ViewRay on 7 of the 13 factors compared between the two stocks.

AxoGen (NASDAQ:AXGN) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, profitability, institutional ownership, valuation, earnings and dividends.

Profitability

This table compares AxoGen and ViewRay's net margins, return on equity and return on assets.

Volatility and Risk

AxoGen has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its share price is 36% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for AxoGen and ViewRay, as provided by MarketBeat.com.

AxoGen presently has a consensus target price of $17.90, indicating a potential upside of 24.22%. ViewRay has a consensus target price of $4.4286, indicating a potential upside of 15.93%. Given AxoGen's stronger consensus rating and higher possible upside, research analysts clearly believe AxoGen is more favorable than ViewRay.

Insider and Institutional Ownership

77.7% of AxoGen shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 6.9% of AxoGen shares are held by company insiders. Comparatively, 15.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings & Valuation

This table compares AxoGen and ViewRay's revenue, earnings per share (EPS) and valuation.

AxoGen has higher revenue and earnings than ViewRay. AxoGen is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Summary

AxoGen beats ViewRay on 8 of the 13 factors compared between the two stocks.

Cutera (NASDAQ:CUTR) and ViewRay (NASDAQ:VRAY) are both small-cap computer and technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, analyst recommendations, risk, profitability and valuation.

Profitability

This table compares Cutera and ViewRay's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Cutera and ViewRay's top-line revenue, earnings per share (EPS) and valuation.

Cutera has higher revenue and earnings than ViewRay. Cutera is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Cutera has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500.

Insider & Institutional Ownership

85.9% of Cutera shares are owned by institutional investors. Comparatively, 83.0% of ViewRay shares are owned by institutional investors. 2.3% of Cutera shares are owned by company insiders. Comparatively, 15.5% of ViewRay shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a breakdown of current ratings and target prices for Cutera and ViewRay, as reported by MarketBeat.

Cutera presently has a consensus price target of $26.00, suggesting a potential upside of 10.78%. ViewRay has a consensus price target of $4.4286, suggesting a potential upside of 15.93%. Given ViewRay's higher possible upside, analysts clearly believe ViewRay is more favorable than Cutera.

Summary

Cutera beats ViewRay on 9 of the 14 factors compared between the two stocks.

TransMedics Group (NASDAQ:TMDX) and ViewRay (NASDAQ:VRAY) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares TransMedics Group and ViewRay's net margins, return on equity and return on assets.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for TransMedics Group and ViewRay, as reported by MarketBeat.

TransMedics Group presently has a consensus price target of $19.00, suggesting a potential upside of 34.18%. ViewRay has a consensus price target of $4.4286, suggesting a potential upside of 15.93%. Given TransMedics Group's higher probable upside, equities analysts plainly believe TransMedics Group is more favorable than ViewRay.

Institutional & Insider Ownership

74.3% of TransMedics Group shares are held by institutional investors. Comparatively, 83.0% of ViewRay shares are held by institutional investors. 13.1% of TransMedics Group shares are held by company insiders. Comparatively, 15.5% of ViewRay shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Volatility and Risk

TransMedics Group has a beta of 1.94, suggesting that its stock price is 94% more volatile than the S&P 500. Comparatively, ViewRay has a beta of 0.64, suggesting that its stock price is 36% less volatile than the S&P 500.

Valuation and Earnings

This table compares TransMedics Group and ViewRay's revenue, earnings per share (EPS) and valuation.

TransMedics Group has higher earnings, but lower revenue than ViewRay. TransMedics Group is trading at a lower price-to-earnings ratio than ViewRay, indicating that it is currently the more affordable of the two stocks.

Summary

TransMedics Group beats ViewRay on 7 of the 13 factors compared between the two stocks.